Pragmatic Clinical Trial Comparing Smoking Cessation Interventions among Underserved Patients who are referred for Lung Cancer Screening

Enrolling By Invitation
99 years and younger
All
Phase 3
850 participants needed
1 Location

Brief description of study

Low-dose computed tomography (LDCT) screening reduces mortality among current and former smokers at high risk for lung cancer, and is widely recommended by national guidelines. LDCT also increases access to care and thus provides an opportunity to deliver smoking cessation interventions to current smokers in conjunction with this screening. As the burdens of smoking are greatest, and the effectiveness of standard interventions lowest, among patients who are black, Hispanic, from rural residences, and/or are less educated or have lower incomes, such underserved patients are at high risk for poor smoking-associated health outcomes. Correspondingly, they may stand to preferentially benefit from smoking cessation interventions delivered in conjunction with LDCT. However, it is unknown which interventions best promote cessation in the screening context. By comparing standard with more intensive interventions, this trial among 3,200 current smokers in four health systems will address the decisional uncertainty facing health systems regarding how best to help high-risk smokers quit.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: - 99 Years
  • Gender: All
Updated on 01 Aug 2024. Study ID: 833713
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research